{"brief_title": "A Study of ABT-751 in Patients With Renal Cell Cancer", "brief_summary": "The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with renal cell cancer. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.", "condition": ["Renal Cell Cancer"], "intervention_type": ["Drug"], "intervention_name": ["ABT-751"], "criteria": "Inclusion Criteria - Renal Cell Carcinoma. - Recurrent tumor. - At least 6 weeks post-nephrectomy. - Able to tolerate normal activities of daily living. - Adequate bone marrow, kidney, and liver function. Exclusion Criteria - Pregnant or breast feeding. - Anti-tumor therapy within 4 weeks of the start of ABT-751 administration. - CNS metastasis.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Carcinoma, Renal Cell"], "id": "NCT00073112"}